LinkedIn
WebsiteIntroduction
Turn Therapeutics Inc. (NASDAQ: TTRX) is a pharmaceutical and medical device company headquartered in Calabasas, California. Founded in 2015 by Bradley Burnam, the company utilizes its proprietary PermaFusion® platform to enhance transdermal and transmucosal delivery of active pharmaceutical ingredients. Its programs encompass dermatology, wound care, infection control, and nasal decolonization.
| Ticker | Exchange | Price (2025-10-09) | % Change | Volume |
|---|---|---|---|---|
| TTRX | NASDAQ | $31.49 | +349.86% | 2,310,921 |
Corporate Structure
Prior to its October 8, 2025 listing, Turn Therapeutics was privately held with 11–50 employees, according to its LinkedIn profile. Key executives and board members include:
- Bradley Burnam, Chief Executive Officer & Founder
- Dr. Neil Ghodadra, Chief Medical Officer, Board Director
- Zuraiz Chaudhary, CPA, Chief Accounting Officer, VP Finance
- Muhammad Zubair, Controller
- Arthur Golden, Board Observer & Outside Counsel
- Andrew Gengos, Board Director
- Avi Chesed, Board Director
The company holds more than 15 patents and has three FDA-cleared medical devices on the market.
Pharmaceutical Innovation by SHAMBHAVI SINGH
Recent Developments and News
On October 7, 2025, the SEC certified Turn Therapeutics’ securities for Nasdaq listing (Form 8-A) and registered employee-plan shares under an S-8 filing. The following day, the company filed a 424B4 prospectus registering 17,868,760 shares for resale by existing shareholders. Trading commenced on October 8, 2025, under the ticker TTRX, and Bradley Burnam participated in ringing the Nasdaq closing bell on the same day.
According to Nasdaq, in the after-hours session on October 8, shares increased by 134.29% to $16.40. By October 9, 2025, the stock price reached $31.49, reflecting a 349.86% gain from its inaugural trading price.
Turn Therapeutics held an open investor session on September 25, 2025, to discuss its platform and clinical pipeline.
Financial and Strategic Aspects
The October 8, 2025, 424B4 filing indicates a resale registration of 17,868,760 shares, following a Regulation A round that concluded on June 27, 2025, at $11.65 per share with 41,805 shares sold. Without firm-commitment underwriting, trading is expected to exhibit volatility.
As an emerging growth company, Turn Therapeutics operates under reduced disclosure requirements. Founder Burnam maintains control of more than 50% of voting power, which may influence corporate governance and strategic decisions.
The PermaFusion platform underpins three FDA-cleared medical devices and supports drug candidates for atopic dermatitis, onychomycosis, and nasal MRSA decolonization. Preliminary data suggest potential efficacy rates of 70–85% for treating onychomycosis (based on a sample size of 100) and 99.9% effectiveness against MRSA in vitro. The company is pursuing QIDP designation for its antimicrobial formula.
An S-8 registration dated October 7, 2025, pertains to securities under the 2025 Omnibus Incentive Plan, which aligns employee interests with long-term goals.
Market Position and Industry Context
The wound care and dermatology markets face challenges related to antibiotic resistance and the limited efficacy of existing topical agents, with CDC-reported antifungal efficacy ranging from 6% to 16%. Turn Therapeutics’ formulations target high-need indications with potential applications in a multibillion-dollar antifungal market. Its devices have recorded over 200,000 human uses with zero reported adverse events. The company operates within a competitive biotech landscape alongside firms in precision oncology and regenerative medicine, which typically rely on investor-driven catalysts for valuation.
tl;dr
On October 8, 2025, Turn Therapeutics began trading on NASDAQ under TTRX, with its share price reaching $31.49 on October 9, reflecting a 349.86% gain from its debut price. The company filed a 424B4 prospectus for 17.9 million shares on October 8 and an S-8 for employee plans on October 7. Founder Bradley Burnam retains a majority of voting power. The PermaFusion® platform supports three FDA-cleared devices and clinical programs for eczema, toenail fungus, and MRSA decolonization. As an emerging growth company with a controlled governance structure, trading volatility is anticipated as the pipeline progresses towards regulatory milestones.
